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Abstract
Background: Bloodstream infections due to Candida species cause significant morbidity and mortality, and the
epidemiology of Candida infection is changing. Surveillance for candidemia is necessary to detect trends in species
distribution and antifungal resistance.
Methods: The medical and electronic records of all patients who had candidemia at the authors’ hospital from
2009 to 2011 were reviewed for demographic data and clinical information, including the infecting Candida species,
resistance to antifungals and survival, and the presence of risk factors associated with candidemia.
Results: A total of 133 distinct episodes of candidemia were identified over the study period. The annual incidence
of candidemia ranged between 0.71 and 0.85 cases/1000 hospital discharges. The most frequent Candida species
were C. tropicalis (28.6%), followed by C. albicans (23.3%) and C. parapsilosis (19.5%). The rates of susceptibility to
antifungal agents were as followed: voriconazole (97.8%), itraconazole (69.5%), fluconazole (46.1%), ketoconazole
(38.9%). Out of 131 evaluable patients, 34 (26.0%) died within 30 days from the onset of candidemia. C. tropicalis
candidemia was associated with the highest mortality rate (44.7%). Regarding the crude mortality in the different
units, patients in Hemato-Oncology ward had the highest mortality rate (66.7%), followed by patients in
cardiovascular wards and ICU (57.1% and 25.6%, respectively). Predictors of 30-day mortality were identified by
uni- and multivariate analyses. Complicated abdominal surgery, presence of central venous catheter (CVC), neutropenia,
candidemia due to C. tropicalis and poor treatment with fluconazole were significantly associated with the 30-day
mortality. Presence of CVC (odds ratio[OR] = 4.177; 95% confidence interval [CI] = 1.698 to 10.278; P = 0.002) was the
only independent predictor for mortality in the multivariate analysis.
Conclusion: This report provides baseline data for future epidemiological and susceptibility studies and for the
mortality rates associated with candidemia in our hospital. The knowledge of the local epidemiological trends in
Candida species isolated in blood cultures is important to guide therapeutic choices.
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Background
Candida spp. is one of the most frequent pathogens iso-
lated in bloodstream infections (BSI), and is associated
with significant morbidity and mortality [1,2]. During
the past two decades, the incidence of candidemia has
been doubled and Candida spp. currently ranks as the
fourth and the seventh most common bloodstream
pathogen in North American and European studies [3,4].
The reasons for the increasing candidemia rates include
improved detection as well as increase in patient-
population at risk, such as invasive procedures and de-
vices, broad-spectrum antimicrobial agents, advanced
life-support and aggressive chemotherapy are more ex-
tensively used [5].
Candidemia have been associated with high crude
and attributable mortality rates, especially among crit-
ically ill patients. The crude mortality rate of these in-
fections is 40%-75% and the attributable mortality of
candidemia has been estimated at 25%-38% [6,7]. In
addition, an increase of 30 days in the length of hos-
pital stay among patients surviving these infections has
been demonstrated [8]. The economic impact of these
infections is also important: candidemia has been asso-
ciated with increased costs of care and prolonged hos-
pitalization [9].
Historically, Candida albicans is the most common
cause of candidemia worldwide. However, in recent years,
some studies have reported an increase of candidemia due
to non-albicans Candida species, with the threat of in-
creased mortality and antifungal drug resistance [10,11].
The intrinsic and emerging resistance to azoles actually
represents a major challenge for empirical therapeutic and
prophylactic strategies [12].
The epidemiology of candidemia shows a wide variation
among different countries. For example, an increasing in-
cidence of candidemia in Iceland was reported for the
period between 2000 and 2011 [13], but the similarity was
not observed in Switzerland, where a national surveillance
study showed that the incidence of candidemia had
remained unchanged during the period of 1991 to 2000
[4]. Despite the epidemiology of candidemia has been
studied extensively in the United States, Europe, and some
countries in South America, very few studies have
addressed these issues in China, where the differences
about the demographic characteristics, health care prac-
tices, patterns using blood cultures, and antibiotic usage
as well as the resistance situation do exist compared to
other countries. In the present study, a three-year retro-
spective analysis was conducted to evaluate the incidence,
species distribution, the associated resistance patterns of
Candida species for the contemporary azole antifungal
agents, outcome of candidema BSI and risk factors for




In our previous study, we developed two enzyme-linked
immunosorbent assays to detect specific antibodies against
Candida Eno and Fba1, and investigated the diagnostic
value for invasive Candida infections by analyzing sera
from patients with candidemia [14]. The purpose of
current study was to investigate the state of Candida inva-
sive infection. We conducted a retrospective observational
study of computerized laboratory records of positive blood
cultures at Jinling Hospital (Nanjing, China), a 1,800 beds
tertiary care hospital with about 55,000 admissions per
year from January 2009 to December 2011. The target
population consisted of hospitalized patients presenting
risk factors for candidemia, especially patients receiving
broad-spectrum antibiotics, immunosuppressive therapy,
parenteral nutrition, abdominal/thoracic surgery and he-
matopoietic transplantation, or those patients who had a
long intensive care unit stay or acute renal failure. An
episode of candidemia was defined as the isolation of a
Candida species from blood culture in a patient with tem-
porally related clinical signs and symptoms, such as fever,
chills, or hypotension. For each patient, only the first epi-
sode of candidemia was included. Patients whose cultures
grew >1 species of Candida were excluded from the ana-
lysis and all data were collected by using the electronic
medical records. The following data were retrospectively
collected: basic demographics, underlying disease, the spe-
cific fungal pathogen and species, resistance to antifungals
and survival. The presence of risk factors associated with
candidemia were also collected: systemic corticosteroid
treatment (a dose equivalent to prednisone 10 mg/d for at
least 14 days), neutropenia (absolute neutrophil count
<500 cells/μl), complicated abdominal surgery (severe
acute pancreatitis, and complex ventral hernia), acute
renal failure (sudden and often temporary loss of kidney
function with nitrogen waste retention and hypou-
rocrinia), indwelling central vascular catheter, intensive
care unit hospitalization or mechanical ventilation. Early
mortality was defined as death within seven days and late
mortality as death between seven and 30 days [15]. The
study protocol was approved by the Medical Ethics Com-
mittee of Jinling hospital.
Organism identification
A volume of 3 ml blood for children and 5 ~ 10 ml blood
for adults was collected aseptically by skin venipuncture
taken from different parts of each patient. The blood
was inoculated into both BacT/AlerT 3D aerobic and
anaerobic vials (Becton Dickinson). All positive cultures
were manually sampled and inoculated on CHROMagar
Candida medium (CHROMagar Company, Paris France)
to ensure viability and purity. An aliquot was Gram-stained
for preliminary identification of the microorganism. Identi-
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fication of all species was confirmed with the Vitek-2
system (bioMerieux, France).
Agar diffusion method
The growth inhibition zone and the category (resistant,
intermediate and susceptible) were determined for flucon-
azole (FLC), itraconazole (ITC), ketoconazole (KTC),
voriconazole (VOR), using a commercial agar diffusion
test with Neo-Sensitabs® tablets (Rosco, Denmark). Neo-
Sensitabs® sensitivity testing is a standardized agar diffu-
sion method which includes antifungal agents in tablets
of 9 mm of diameter with FLC (25 μg), ITC (8 μg), KTC
(15 μg) and VOR (1 μg). Neo-Sensitabs® assay was per-
formed according to the manufacturer’s instructions [16].
Inocula contained 5 × 105 cells/ml and were prepared
from an overnight subculture on Sabouraud glucose
agar (Difco, USA), getting suspensions corresponding to
McFarland 0.5 standard and then diluted (1:1) with sterile
saline solutions. For C. krusei isolates inocula were equiva-
lent to McFarland 0.5 standard, diluted 1:10 in saline solu-
tions. Two milliliters of each inoculum suspensions were
poured onto the agar surface and later removing the liquid
in excess. Opened plates were dried at 35°C for 15 min be-
fore tablets will be placed on the agar surface.
Shadomy modified medium was used (Yeast Nitrogen
Base, asparagine and glucose) with phosphate buffer to
pH 7 and containing chloramphenicol to avoid bacterial
contamination. Media was heated at 100°C during 15 min,
and then cooled to 60°C before pouring the medium in
Petri dishes (12 cm× 12 cm). A pre-diffusion drying was
made at 37°C during 15 min. After an incubation period
of 20-24 h, the inhibition diameter zones were read in
mm with a caliper (Mitutoyo, Japan). Zone diameters were
measured to the nearest whole millimeter at a point in
which there was a prominent reduction of growth (80%
for azoles). Depending on the diameter of the inhibition
zone, Candida strains were classified as susceptible (S),
intermediate (I) or resistant (R) to tested antifungals. The
basic criterion according to manufacturers instructions
was as follows: FLC (S ≥ 19 mm, I18~15 mm, R ≤ 14 mm);
ITC (S≥ 15 mm, I14~10 mm, R < 10 mm); KTC (S≥ 28 mm,
I27~21 mm, R ≤ 20 mm); VOR (S ≥ 17 mm, I16~14 mm,
R ≤ 13 mm).
Statistical analyses
In the assessment of predictors of poor outcome, we
compared patients who survived until day 30 after the
incident candidemia with those who died. Univariate
analysis was perforemd using Fisher exact test or Chi-
squared test for categorical variables. All variables with
P-value < 0.1 by univariate analysis were entered in a lo-
gistic regression model. Kaplan-Meier curves were
constructed to assess survival, and curve comparisons
were performed by the Log Rank test. All tests were
two-tailed and a level of significance of P < 0.05 was con-
sidered statistically significant. Statistical analysis was
performed using SPSS 18.0 for Windows (SPSS, Chicago,
IL, USA).
Results
A total of 133 distinct episodes of candidemia (130 adults
and 3 children <15 years of age) were identified during the
study period. Most candidemia was reported in adults
(97.7%). More candidemia occurred among males (68.4%)
than females, mainly in those over 60 years of age
(Table 1). The mean annual incidence of candidaemia was
0.77 per 1000 admission. The incidence of candidemia in-
creased from 0.71 in 2009 to 0.85 episodes/1000 admis-
sion in 2011. But the change in incidence over time did
not reach statistical significance. The demographic and
clinical characteristics of the patients are summarized in
Table 1. Most patients had one or more comorbidity at
the time of the diagnosis of candidaemia. The most com-
mon underlying conditions documented prior to candidemia
were intestinal fistula/abdominal infection (55.7%), re-
spiratory dysfunction (12.8%), and gastrointestinal path-
ology (10.2%).
The percentages of the three most common Candida
spp. isolated were as follows: C. tropicalis (28.6%), C.
albicans (23.3%) and C. parapsilosis (19.5%) (Table 1). The
causative organism varied according to age of patients and
their underlying diseases. With increasing age, a reduction
in the percentage of C. albicans (from 33.3% to 23%) and
C. tropicalis (from 33.3% to 27.9%) and a significant in-
crease of C. parapsilosis (from 0 to 21.3%) was observed.
Non-albicans Candida species were isolated with the
highest frequency from patients with respiratory dysfunc-
tion (82.4%) and haematological malignancies (83.3%), in
which C. tropicalis was the predominant species (64.7%
and 83.3%, respectively).
The distribution of isolated Candida species is shown in
Figure 1. Globally, the high rates of candidemia infection
are not limited to ICU but also occurred on general wards.
Out of 133 evaluable patients, 51 (38.3%) were hospital-
ized in ward of general surgery, this proportion being a
small amount higher than that which arose from patients
in ICU (23.3%). The distribution of Candida albicans and
non-albicans Candida species differed according to the
type of patient population and risk factors, as shown in
Figure 1. In patients with hematologic malignancies, C.
albicans accounted for 16.7% of the cases and C. tropicalis
for 83.3%; In ICU C. albicans was isolated in 17.9% of the
cases, C. tropicalis in 30.8% and C. parapsilosis in 20.5%;
on the other hand in oncology C. albicans was isolated in
50% of the cases.
Table 2 summarizes the results of in vitro susceptibility
testing of bloodstream isolates of Candida in the study.
Consistent with previous reports [17,18], vorconazole
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demonstrated excellent in vitro potency against Candida
species, nearly all strains (97.8%) were susceptible to VOR.
With regard to KTC, the rate of resistant is particularly
high in Candida spp. (61.9%), almost all isolates were re-
sistant to KTC. ITC resistance was observed for 30.5% of
all Candida isolates evaluated and was also highest among
C. glabrata isolates (90.9% resistance). Most strains (53.9%)
became resistant to FLC, only 8 C. albicans BSI isolates
(25.8%) collected during the 3-year surveillance program
were reported as resistant. Decreased susceptibility to FLC
was mostly seen with C. glabrata (90.9% resistance) and
C. tropicalis (68.4% resistance). The percentages of yeast
isolates with resistance and decreased susceptibility to
FLC were similar during the three phases.
Table 1 Patient characteristics and incidence (episode/1000 admission)
Candida species
Total C. tropicalis C. albicans C. parapsilosis C. glabrata C. krusei C. guilliermondii Other*
(n = 133) (n = 38) (n = 31) (n = 26) (n = 11) (n = 3) (n = 6) (n = 18)
100.0% 28.6% 23.3% 19.5% 8.3% 2.3% 4.5% 13.5%
Patients characteristic
Age (years)
1-14 3(2.3) 1(33.3) 1(33.3) 0(0) 0(0) 0(0) 0(0) 1(33.3)
15-49 29(21.8) 7(24.1) 9(31.0) 5(17.2) 3(10.3) 0(0) 1(3.4) 4(13.8)
50-65 40(30.1) 13(32.5) 7(17.5) 8(20.0) 3(7.5) 1(2.5) 4(10.0) 4(10.0)
>65 61(45.9) 17(27.9) 14(23.0) 13(21.3) 5(8.2) 2(3.3) 1(1.6) 9(14.8)
Gender
Male 91(68.4) 28(30.8) 20(22.0) 18(19.8) 6(6.6) 2(2.2) 2(2.2) 15(16.5)
Female 42(31.6) 10(23.8) 11(26.2) 8(19.0) 5(11.9) 1(2.4) 4(9.5) 3(7.1)
Underline diseases n (%)
Intestinal fistula/abdominal infection 74(55.7) 14(18.9) 20(27.0) 15(20.3) 6(8.1) 3(4.1) 5(6.8) 11(14.9)
Solid tumor 8(6.0) 2(25.0) 2(25.0) 1(12.5) 2(25.0) 0(0) 0(0) 1(12.5)
Respiratory dysfunctiona 17(12.8) 11(64.7) 3(17.6) 1(5.9) 0(0) 0(0) 0(0) 2(11.8)
Gastrointestinal pathologyb 14(10.5) 4(28.6) 1(7.1) 5(35.7) 1(7.1) 0(0) 1(7.1) 2(14.3)
Haematological malignancy 6(4.5) 5(83.3) 1(16.7) 0(0) 0(0) 0(0) 0(0) 0(0)
Acute renal failurec 11(8.3) 1(9.1) 3(27.3) 4(36.4) 2(18.2) 0(0) 0(0) 1(9.1)
Burns 3(2.3) 1(33.3) 1(33.3) 0(0) 0(0) 0(0) 0(0) 1(33.3)
Receipt of corticosteroids 76(57.1) 21(27.6) 17(22.4) 15(19.7) 5(6.6) 1(1.3) 2(2.6) 15(19.7)
Chemotherapy 6(4.5) 5(83.3) 1(16.7) 0(0) 0(0) 0(0) 0(0) 0(0)
Presence of CVCd 61(45.9) 19(31.1) 13(21.3) 11(18.0) 5(8.2) 2(3.3) 4(6.6) 7(11.5)
Parenteral nutrition 61(45.9) 20(32.8) 18(29.5) 6(9.8) 8(13.1) 1(1.6) 3(4.9) 5(8.2)
Mechanical ventilation 17(12.8) 6(35.3) 5(29.4) 2(11.8) 2(11.8) 0(0) 0(0) 2(11.8)
In the ICU at diagnosis 39(29.3) 14(35.9) 9(23.1) 8(20.5) 3(7.7) 2(5.1) 0(0) 3(7.7)
Neutropeniae 6(4.5) 2(33.3) 2(33.3) 0(0) 2(33.3) 0(0) 0(0) 0(0)
Dialysis 2(1.5) 0(0) 1(50.0) 1(50.0) 0(0) 0(0) 0(0) 0(0)
Exposition to antibiotics 80(60.2) 29(36.3) 23(28.8) 20(25.0) 3(3.8) 2(2.6) 1(1.3) 2(2.6)
Treatment with fluconazole 61(45.9) 23(37.7) 18(29.5) 5(8.2) 3(4.9) 3(4.9) 2(3.3) 7(11.5)
Incidence (episodes/1000 admissions)
2009 0.71 0.19 0.22 0.11 0.06 0.02 0.04 0.06
2010 0.77 0.18 0.15 0.23 0.02 0.03 0.03 0.15
2011 0.85 0.31 0.19 0.13 0.13 0 0.03 0.12
*Others include: C. pelliculosa(8), C. famata(7) and C. haemulonii(2).
aIncludes the following diseases: pneumonia, chronic obstructive pulmonary disease, and acute respiratory distress syndrome.
bIncludes the following diseases: cholecystitis, pancreatitis, peritonitis, and hepatitis.
cAcute renal failure was defined as sudden and often temporary loss of kidney function with nitrogen waste retention and hypourocrinia.
dCVC central venous catheter.
eNeutropenia was defined as absolute neutrophil count <500 cells/μl.
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Outcome at day 30 was available for 131 episodes; pa-
tients in the remaining 2 episodes were lost to follow up.
The crude mortality rate was 26.0%; Seven patients died
within 48 hours of obtaining the blood culture, the time
by which positive blood culture reports became avail-
able. This overall mortality rate varied according to the
patients with different species of Candida, as well as the
underlying disease or condition, the highest mortality
rate was observed for C. tropicalis fungemia (44.7%).
Haematological malignancy (66.7%), cardiovascular disease
(57.1%), and intensive care in adults (25.6%) were associ-
ated more frequently with death during the study period.
Univariate predictors of poor outcome in candidemia
is shown in Table 3. For candidemic patients, the vari-
ables associated with 30-day mortality were as follows:
complicated abdominal surgery, presence of CVC, neu-
tropenia, candidemia due to C. tropicalis. Major factor
associated with 30-day survival was receipt of flucona-
zole as primary treatment for candidemia. Because neu-
tropenia was associated with poor outcome and this
variable was available in only 6 of the 131 patients, this
variable was not included in the multiply logistic regres-
sion model. As shown in Table 4, predictors of 30-day
mortality by multivariate analysis among patients with
candidemia were presence of CVC (OR 4.177; 95% CI 1.698-
10.278; P = 0.002).
Discussion
In recent years, some studies have reported that the inci-
dence of candedimia is increasing in many hospitals
around the world. Our data show that in our hospital
the incidence of candidemia has increased steadily in the
Figure 1 Distribution of the Candida species according to underlying pathology/medical care (n).
Table 2 Antifungal susceptibility of Candida bloodstream isolates in patients during the study period
Fluconazole Itraconazole Ketoconazole Voriconazole
Species No. of isolates tested %S# No. of isolates tested %S No. of isolates tested %S No. of isolates tested %S
C. albicans 31 23 (74.2) 31 29 (93.6) 6 3 (50.0) 22 22 (100.0)
C. parapsilosis 26 15 (57.7) 26 25 (96.2) 2 1 (50.0) 22 22 (100.0)
C. glabrata 11 1 (9.1) 11 1 (9.1) 1 0 (0) 5 5 (100.0)
C. tropicalis 38 12 (31.6) 38 25 (65.8) 5 0 (0) 23 21 (91.3)
C. krusei 3 0 (0) 3 1 (33.3) 1 0 (0) 3 3 (100.0)
C. guilliermondii 6 4 (66.7) 6 5 (83.3) 0 0 (0) 5 5 (100.0)
Other* 16 4 (25.0) 16 5 (31.3) 3 3 (100.0) 12 12 (100.0)
Total 128 59 (46.1) 131 91 (69.5)* 18 7 (38.9) 92 90 (97.8)
*; Others include: C. pelliculosa, C. famata and C. haemuloni.
#; Abbreviations: S susceptible.
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past three years in parallel with medical technological
advances. The incidence is somewhat higher than that
reported for centers in Denmark (0.41 case per 1000 ad-
missions) [19], Israel (0.50 case per 1000 admissions)
[20], China (0.53 cases per 1000 admissions) [21], and
much lower than that reported in Brazil (1.87 cases per
1000 admissions) [22]. The differences in candidemia
rates between countries may reflect differences in demo-
graphic characteristics, variations in health care practice,
patterns using blood cultures and long duration of anti-
bacterial usage as well as the resistance situation.
Neonates and infants have historically been populations
with some of the highest rates of candidemia [23-29]. In
our study, BSI by candida species occurred more fre-
quently among males, mainly in those over 65 years old.
The reasons for the shift in burden from neonates to
adults are likely multifactorial; some contribution may be
due to changes in the prevalence of risk factors in the
adult population. Increases in common risk factors such
as ICU admission [30,31], or numbers of patients receiv-
ing immunosuppressive therapies [32] may have resulted
in increase in the overall pool of patients at high risk for
candidemia. The difference in the distribution of cases be-
tween genders could be related to the predominant pres-
ence of male patients in units where the use of invasive
devices, broad-spectrum antibiotics, extensive surgical
procedures, or advanced life support is frequently used.
Over the past 20 years, a shift towards non-albicans
Candida species has been reported previously from the
USA, Europe and Australia, although the precise pattern
of causative species varies across countries [5]. The find-
ings from our surveillance are partially supportive of
these reports. We observed a significant predominance
of non-albicans Candida species (76.7%), with C. tropicalis
being the most common isolate (28.6%), followed by C.
albicans (23.3%), C. parapsilosis (19.5%) and C. glabrata
(8.3%). Traditionally, C. tropicalis has been the second
most common Candida species recovered from blood
[33]. Similarly, as previously reported at a hospital in
China, C. albicans (57.8%) continued to play a dominant
role in candidemia, followed by C. tropicalis (12.8%) [34].
In our report, C. tropicalis surpassed the other Candida
species to become the most common species, we
recognize that this finding may simply be a result of the
small sample size, and the further studies with larger sam-
ple size are needed to verify it. It is worth mentioning that
eight C. pelliculosa, seven C. famata and two C. haemulonii
isolates were recovered during the study period, sug-
gesting the diversity of the etiologic agents. ARTEMIS
DISK Global antifungal surveillance also found an in-
crease of the involvement of less-common Candida spe-
cies during the 10.5-year study period and showed that
species identification is important to diagnosis and sur-
veillance [35].
As already reported [36]. non-albicans Candida spe-
cies were predominant in patients with haematological
malignancies (83.3%), a finding in accordance with the
global results of the ECMM survey [7]; moreover, C.
tropicalis was frequently isolated in this group of pa-
tients, the prevalence of C. tropicalis among patients
with haematological malignancies is consistent with
previous reports [19].
The antifungal susceptibility patterns revealed that
voriconazole has excellent in vitro activity overall against
Candida species. Successful salvage therapy with vori-
conazole for the treatment of candidemia in patients in-
tolerant or refractory to other antifungal agents has been
reported [37]. Some studies showed that voriconazole
may be a suitable agent for salvage therapy of invasive
candidiasis, even in the setting of previous azole expo-
Table 3 Factors associated with 30-day mortality by







Median age, years (range) 61 (0-88) 69 (0-73) 0.58
Gender (male:female) 68:29 23:11 0.889
In the ICU at diagnosis, n (%) 30 (30.9) 9 (26.5) 0.457
Mechanical ventilation, n (%) 10 (10.3) 7 (20.6) 0.109
Parenteral nutrition, n (%) 43 (44.3) 18 (52.9) 0.952
Complicated abdominal surgery, n (%) 21 (21.6) 14 (41.2) 0.019
Presence of CVC, n (%) 34 (35.1) 27 (79.4) <0.001
Receipt of corticosteroids, n (%) 53 (54.6) 23 (67.6) 0.397
Neutropenia, n (%) 2 (2.1) 4 (11.8) 0.015
Species, n (%)
C. albicans 25 (25.8) 6 (17.6) 0.508
C. tropicalis 21 (21.6) 17 (50.0) 0.002
C. parapsilosis 19 (19.6) 5 (14.7) 0.444
C. glabrata 8 (8.2) 3 (8.8) 0.928
C. krusei 2 (2.1) 1 (2.9) 0.575
Treatment with antibiotics, n (%) 57 (58.8) 23 (67.6) 0.600
Treatment with fluconazole, n (%) 51 (52.6) 10 (29.4) 0.019
ICU intensive care unit, CVC central venous catheter.
Table 4 Factors associated with 30-day mortality by
multivariate analysis






Presence of CVC 4.177 1.698–310.278 0.002
C. tropicalis 1.705 0.809–33.593 0.161
Treatment with fluconazole 0.523 0.247–31.110 0.091
CVC central venous catheter.
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sure and C. krusei infection [36,38]. Most publications
on antifungal resistance over the past 10 years have been
concerned with resistance to triazole antifungals, espe-
cially fluconazole, itraconazole, and ketoconazole. For
ketoconazole, it showed the exsitence of a sensitivity of
38.1% of strains studied, lower than the other three
azoles. Ketoconazole resistance was observed in 50% of
C. albicans and C. parapsilosis, respectively. Itraconazole
resistance was observed for 30.5% of all Candida species
and was also highest among C. glabrata (90.9% resist-
ance), this sensitivity decline was similar to that previ-
ously published in Iowa Organisms Study [39]. In recent
years, resistance to azole antifungal agents among Can-
dida spp. is still uncommon. In Iceland, 97.3% of the
Candida spp. isolates tested were susceptible to flucona-
zole [13]. A similar data has been reported from North
India [40]. In contrast to other reports, antifungal resist-
ance was a notable finding in our study and was mainly
restricted to fluconazole. Our proportion of fluconazole-
resistant isolates (53.9%) was higher than the rates ob-
served with spain (9.8%) [41]. We propose two potential
reasons, first, the number of isolates in this study is still
not high enough, therefore the rate of azole resistance is
higher than clinical reports. Second, the increasing use
of fluconazole as antifungal therapy leads to a reduction
in susceptibility and the appearance of resistant strains.
Some reportes have demonstrated that candidemia due
to non-albicans species increased and that was appar-
ently correlated with an increasing use of azoles for
prophylaxis or empirical treatment [42], in our study, al-
most all patients received empirical therapy, 65(45.9%)
patients were treated with fluconazole, followed by
voriconazole (18.8%), and caspofungin (11.3%). For the
latter reason, it would be convenient to carry out anti-
fungal susceptibility studies in order to establish the
in vitro activities of antifungal agents against local iso-
lates and also to detect shifts toward resistance as early
as possible. When analyzed by species, apart from the
intrinsically fluconazole-resistant species (C. krusei), the
highest rate of resistance to fluconazole was for C.
glabrata and C. tropicalis (more than 50%), which was
consistent with other studies in whom the greatest re-
sistance to fluconazole also showed C. glabrata (36%)
[41]. Furthermore, discrepancies in vitro susceptibility to
FLC rate of different strains studied in this single-center
study could be associated to differences in species distri-
bution of isolates tested in this study.
In the present study we decided to analyze prognostic
factors in patients with candidemia, we found that com-
plicated abdominal surgery, presence of CVC, neutro-
penia, candidemia due to C. tropicalis, poor treatment
with fluconazole were predictors of mortality in the uni-
variate analysis. Of all the variables significantly associ-
ated with mortality in the univariate analysis, presence
of CVC was the only predictive factor of mortality in the
multivariate analysis. This is in agreement with the find-
ings of a hospital population-based surveillance study
[43]. In a study of pediatric candidemia, Candidemia-
associated mortality has been found to be 31-72% [44].
Similarly, the crude 30-day mortality rate in our study
was 26% for all patients with candidemia, which is in
concordance with rates reported from Chinese tertiary-
care centers, ranging from 26.4% to 33.3% [21,34]. A
possible explanation for the relatively low mortality of
nosocomial candidemia is the increase in empirical and/
or pre-emptive use of fluconazole for presumed invasive
candidiasis. Furthermore, although the hospital is a ter-
tiary care hospital it rarely has patients with solid organ
or bone marrow transplants. Thus, on average the pa-
tients in our hospital are less sick than in other hospi-
tals. In our study, C. tropicalis was the species associated
with the highest mortality rate (50%), besides being
raised among the elderly, mortality is particularly high
among patients with cancer (66.7% for haematological
malignancies) as reported previously [33,45,46]. Cer-
tainly the severity of the underlying medical conditions
has greatly influenced the crude mortality rate in these
patient populations.
Conclusions
This report shows that candidemia is a significant source
of morbidity in Nanjing, with a substantial burden of
disease, mortality, and likely high associated costs. We
concede that there are several potential limitations to
the present study. First, this is a single-center study. Our
conclusions might be influenced by the local ecology,
management practices, infections control policy, or our
own susceptibility patterns. Second, our analysis was re-
stricted to adult patients. Therefore, our conclusions
cannot be extrapolated to pediatric populations. Finally,
the results of the multivariate analyses might be influ-
enced by the sample size and the number of variables in-
cluded in the models. However, it would be of immense
value to establish surveillance of candidemia to develop
and evaluate prevention strategies and to monitor for
changes in incidence and resistance.
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